Transcript Slide 1
Painful bladder
(in women)
Professor Douglas Tincello
University of Leicester
Declaration of Interest
• Industry related 2012
– Honorarium for Allergan advisory board
– Honorarium, registration, accomodation for
Ethicon symposium at UKCS
– PI on RELAX study (onaBoNT-A)
• Independent funding
• All funding managed via University business
office
Tincello DG Kuwait Feb 16th -18th 2013
Hypotheses for aetiology?
• Four major theories
– Autoimmune disease
– Chronic infection
– Neurogenic inflammation
– Epithelial permeability
• None sufficient or totally convincing
Tincello DG Kuwait Feb 16th -18th 2013
Bacteria
Viruses
“Toxins”
K+
Antiproliferative factor
?
Cytokines
Histamine
Mast cell
Substance P
Tincello DG Kuwait Feb 16th -18th 2013
Complement
Antiproliferative factor
• APF similar to frizzled 8 protein-related
sialoglycopeptide (Keay J Urol 2005;173:909)
– G protein coupled receptor protein family
– ? Inhibition of proliferation signals
• Specific receptor identified (CKAP4/p63)
– Cytoskeleton associated receptor
– (Conrads et al J Biol Chem 2006;281:37836)
Tincello DG Kuwait Feb 16th -18th 2013
Antiproliferative factor
• Urine of IC patients inhibits urothelial growth
– 86% of IC patient vs 12% cystitis vs 8% controls
– (Keay et al Urol 1998;52:974)
• APF produced by urothelium
– 19/20 bladder urine vs 1/20 renal pelvis urine
–
(Keay et al J Urol 1999;162:1487)
• 95% sensitivity; 94% specificity
– (Keay et al Urology 2001;57(6A):9)
• Irrespective of ethnic origin
– (Zhang et al Urology 2003;61:897)
Tincello DG Kuwait Feb 16th -18th 2013
Antiproliferative factor
• APF inhibits HB-EGF release from urothelium
• Exogenous HB-EGF blocks inhibition
– (Keay et al J Urol 2000;164:2112)
• Hyrdodistention causes APF ↓ & HB-EGF ↑
– (Keay et al J Urol 2000;163:1440)
• APF increases permeability of urothelium
–
(Zhang et al J Urol 2005;174:2382)
• Urothelial cells from IC patients grow slowly
–
(Keay et al Urol 2003;61:1278)
• Gene expression is “non proliferative”
– (Keay et al Physiol Genomics 2003;14:107)
Tincello DG Kuwait Feb 16th -18th 2013
Antiproliferative factor
?
APF
Bacteria
Viruses
“Toxins”
K+
-
Tincello DG Kuwait Feb 16th -18th 2013
HB-EGF
Diagnostic criteria…
• Interstitial cystitis (NIDDK criteria)
– Originally for research, but were adopted
– Tight, specific limits on functional volumes, cystoscopic
findings, symptom severity
– Comprehensive exclusion criteria
• IC/CPPS (Diokno A et al. Int J Urol, 10: S3, 2003)
–
–
–
–
“Pain” includes: burning, pressure, discomfort
At least 3 months’ duration
May be exacerbated by intercourse
Patient must have frequency and urgency
Tincello DG Kuwait Feb 16th -18th 2013
…continued…
•
•
•
•
European Society for the Study of IC/PBS
Consensus statement June 2006
Stop using “interstitial cystitis”
“Bladder pain syndrome”
–
–
–
–
Chronic pain related to bladder
Plus one other symptom
Exclusion of “confusable diseases”
Cystoscopy with hydrodistension and biopsy
Tincello DG Kuwait Feb 16th -18th 2013
Confusable diseases
“The diagnosis
of a
confusable
disease does
not necessarily
exclude a
diagnosis of
bladder pain
syndrome”
A word about cystoscopy
• Cystoscopy is for excluding discrete pathology
– IC & sensory urgency have same leucocytes (Al Hadithi , 2002)
– Mast cells present in up to 40% of SU patients (Frazer, 1993)
– Glomerulations occur in normal bladders (Waxman, 1998)
– Symptoms not related to cystoscopic or urodynamic data
(Messing, Nigro; ICDB study, 1997)
• No longer a requirement for making a diagnosis
Tincello DG Kuwait Feb 16th -18th 2013
Patients…
• Present with bladder pain ± other symptoms
• Pelvic pain can arise from several sources
– common autonomic/visceral pain pathways
– may be a common pathway for diverse initial insult
• Various “pseudonyms”
– urethral syndrome, sensory urgency, vulvodynia, myofascial
syndrome, endometriosis, “chronic pelvic pain”
• Management algorithm to screen for causes
Tincello DG Kuwait Feb 16th -18th 2013
How I assess patients...
• Based upon:
– literature
Nordling J Eur Urol 2004;45:662
O’Leary MP Urol 1997;49:58
Daha LK J Urol 2003;170:807
– Learning from conferences
– clinical experience
Tincello DG Kuwait Feb 16th -18th 2013
Assessment-history
Site, radiation and associations of pain
Duration, and exacerbations in relation to urinary
symptoms (esp bladder filling)
Presence, site and duration of dyspareunia
post coital ache
Frequency and nocturia
Haematuria?
? Proven urinary tract infection
– including fastidious organisms
Tincello DG Kuwait Feb 16th -18th 2013
Assessment-examination
Symphyseal tenderness, sacroiliac tenderness
– (pain on abduction of hips or limitation of ROM)
• Hyperaesthesia in lower abdomen/perineum
– (nerve entrapment)
Vulval erythema or hyperalgesia on cotton swab test
in each quadrant of vestibule
Palpate bladder base, pelvic muscles for tenderness
(trigger points)
reproduction of symptoms
Cervical excitation, masses, endometriosis nodules
Tincello DG Kuwait Feb 16th -18th 2013
Assessment-investigation
Urine culture (including fastidious/anaerobes)
3 day urinary diary
frequency, nocturia
daytime voided volumes vs waking void volume
• Urodynamics
– (sometimes)
• Double fill cystoscopy and hydrodistension
– (sometimes)
Tincello DG Kuwait Feb 16th -18th 2013
Compare daytime
and waking
volumes
All vols usually
Day vols < 350ml
< 350mls
Waking vol > 350ml
Day vols include
>350 mls
PBS likely
PBS unlikely
PBS very
unlikely
Urodynamics ±
cystoscopy
Refer for bladder
retraining
UDS unlikely
to be useful
Urodynamics if
no better
Bladder drill +
PFE
Tincello DG Kuwait Feb 16th -18th 2013
Urodynamics
DO excluded
“PBS”
“Sensory urgency”
Sensation
Sensation
Capacity
Capacity normal
“Normal”
First sensation
<150 ml
First sensation
<150 ml
First sensation
≥ 150 ml
Capacity
<350 ml
Capacity ≥
350ml
(with coaxing!)
Capacity ≥
350 ml
Tincello DG Kuwait Feb 16th -18th 2013
Treatment
• Specific treatment for specific conditions
–
–
–
–
endometriosis
vulvodynia
myofascial syndrome/pelvic muscle trigger points
Sacroiliac or symphyseal joint pain
• PBS symptoms & normal bladder capacity
• PBS and reduced bladder capacity
Tincello DG Kuwait Feb 16th -18th 2013
Normal bladder capacity
• Bladder drill +/- diary to increase functional capacity
• Retrain sensations
• Anticholinergics may be of some benefit
– modulate sensation of urgency & discomfort?
• If no improvement…
– treat as if reduced capacity
Tincello DG Kuwait Feb 16th -18th 2013
Reduced capacity
• “interstitial cystitis” or PBS
–
–
–
–
Quality of published work is poor
Most use NIDDK criteria (most severe patients)
Placebo effect is large
Few RCTs
• Pain control and patient support
• Intravesical therapy
• Oral therapy
• Recent systematic review (Giannantoni 2012 Eur Urol 61:29-53)
Tincello DG Kuwait Feb 16th -18th 2013
Intravesical therapy
• Distension under GA for 10 minutes
– 55% response rate but transient
(Hanno 1991 Semin Urol 9:143; Pontari 1997 Urol 49 (5A):114)
• DMSO (Six to eight weeks of instillations 1-2/week)
– Response rate up to 90%; 40% relapse rate
– No RCT data
(Parkin 1997 Urol 49 (5A):105; Pontari 1997 Urol 49 (5A):114; Peeker 2000 J Urol
164:1912)
• Hyaluronic acid
– success rate of 30-70%
– One randomised trial, no placebo
(Kallestrup 2005 Scand J Urol Nephrol 39:143; Reidl 2008 IUGA J 19:717; Cervigni 2012
IUGA J 23: 1187; Yi-Song 2012 IUGA J in press; Lai M-C 2012 Int J Urol in press)
Intravesical therapy
• Botulinum toxin
– Mixed data from non –RCTs
– 75% improved at 3 months
• 80% fall in pain, 40% in frequency
– 75% relapse by 6 months
– RCT data (n=2) confirm efficacy
• Fall in pain and frequency @ 3/12
• Trigone injection shows greater effect
– 50% reduction in frequency & noturia
(Liu 2007 Urol 10:463; Kuo 2005 Urol Int 75:170; Smith 2004 Urol 64:871; Giannantoni
2008 J Urol 179:1031; 2010 Curr Drug Del 7:1; Kuo 2009 BJU Int 104:657; Pinto 2010 Eur
Urol 58; 360)
Oral treatments
• Cimetidine
– RCT of 400 mg significant reductions in pain and nocturia
(Seshadri 1994 Urol 44:614; Thilagarajah 2001 BJU Int 87:207)
• Pentosan polysulphate
– 3 of 5 RCTs show a difference
– 25%+ improvement in 25% vs 13%
(Parsons 1987 J Urol 138:513; Mulholland 1990 Urol 35:552; Parsons 1993 J Urol
150:845)
• Amitriptyline
– Success of 65-90% (Hanno 1994 Urol Clin N Amer 21:121; Pranikoff 2001
Urol 51 (5A); 179)
– Titration from 25mg nocte to 100mg
(van Ophoven 2004 J Urol 172:533)
Recent data
• Systematic review
– Giannantoni Eur Urol 2012;61:29-53
– 29 RCTs and 57 non random studies
– Standardised mean difference
• 0.8 = large effect
• 0.5 = moderate effect
– Assessed four outcomes
•
•
•
•
IC symptom index
Pain
Urgency
Frequency
IC symptom index
Pain
Urgency
Frequency
Conclusions...
• Cyclosporin A
– Effect on 3 of 4 outcomes (? Data)
• Amitriptyline
– Effect on all four outcomes
– 25mg – 100mg titrated at night
• PPS
– Limited efficacy
– Non-random studies suggest 50% long term effect
Giannantoni Eur Urol 2012;61:29-53
...cont’d...
• BCG
– Limited effect
– Concerns re use from cancer studies
• BoNTA
– Effective at pain relief
– ? Additional effect from trigone injection
• “The inability to propose definite conclusions
from the results coming from most of the
proposed treatments...”
Giannantoni Eur Urol 2012;61:29-53
History, exam,
MSSU, FV Chart
?
Day vols >350 mls
Bladder drill,
alkalinisation
Waking vol > 350ml
Specific
condition
identified
Treat
Y
All vols < 350mls
Better?
Disch’g
N
Normal capacity
Urodynamics
Reduced capacity
Intravesical Rx:
DMSO
BoNT-A
Oral Rx:
cimetidine
amitriptyline
Cystoscopy &
distension
Specific
condition
identified
Treat
Pain clinic